Qatar now has its own population-specific genome resource after researchers at Weill Cornell Medicine in New York and Qatar mapped the genomes of more than 1,000 Qatari nationals.
Latest news from The Englander Institute for Precision Medicine:
One of the biggest challenges in precision medicine is what to do with the mountain of data generated from the sequencing of each tumor – how to parse out the relevant information and make it accessible and useful to the physicians making treatment decisions. Ultimately, such data should be available for a function called Clinical Decision Support. This function as defined by the Federal Office of the National Coordinator for Health Information Technology is “knowledge and person-speci
Moonshot Thinking: Tumor Banking, Data Sharing, and Innovation is key
In what evolved into a cancer moonshot think tank, a special event was held at Weill Cornell Medicine on June 29, one of 270 held in tandem across the United States convened by Vice President Joe Biden, with a national summit at Howard University in Washington, DC.
Dr. Himisha Beltran represented The Englander Institute of Precision Medicine at The American Society of Clinical Oncology (#ASCO16) annual meeting over the weekend in Chicago.
At the meeting, Dr. Himisha Beltran was the chair of a session entitled “Precision Medicine in Advanced Prostate Cancer: Understanding Genomics, Androgen Receptor Splice Variants, and Imaging Biomarkers,” where she spoke about biomarker identification in prostate cancer and how clinicians can use this information to guide treatment decisions.
A subset of treatment-resistant prostate cancer pathologically resembles small cell lung cancer rather than typical prostate cancer, Weill Cornell Medicine and University of Trento investigators discovered in a new study. The scientists say their findings may lead to more effective ways to diagnose and treat neuroendocrine prostate cancer.